Form 4: ADMA Biologics CEO Adam Grossman Reports Acquisition of 252,022 Restricted Stock Units

Adam Grossman, CEO of ADMA Biologics, reports the acquisition of 252,022 restricted stock units and 376,744 stock options, along with adjustments to existing holdings.

Summary

• Adam Grossman, the President and CEO of ADMA Biologics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On February 19, 2025, Grossman acquired 252,022 restricted stock units (RSUs) that will vest quarterly over four years.
• He also acquired 376,744 stock options with an exercise price of $16.07, vesting over four years with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the next three years.
• Following these transactions, Grossman directly owns 2,226,686 shares of common stock, which includes unvested RSUs and shares owned outright.
• He also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
• Grossman directly owns 376,744 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing changes in ownership. The acquisition of equity could be seen as a positive sign of confidence, but it's not overtly bullish.

Positives

• The acquisition of RSUs and stock options by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a long-term commitment from the CEO.

Industry Context

Form 4 filings are standard practice and provide transparency into the holdings and transactions of company insiders. This filing is specific to the CEO's holdings in ADMA Biologics.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to align management's interests with those of shareholders.
• Vesting schedules for RSUs and stock options are typically structured to incentivize long-term performance and retention.
• The specific terms of Grossman's equity awards (vesting schedule, exercise price) would need to be compared to those of executives at comparable biotechnology companies to assess their competitiveness.

Stakeholder Impact

• The change in insider ownership may have a minor impact on shareholder sentiment.
• Employees may view the CEO's increased equity stake as a positive sign of commitment to the company's success.

Key Dates

Keywords

ADMA Biologics, Adam Grossman, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation